Trial Profile
A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Cornerstone Pharmaceuticals Inc
- 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
- 13 Aug 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 22 Apr 2013 New trial record